News Image

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Provided By PR Newswire

Last update: Nov 14, 2024

— Improved loss from operations by 31% —

— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections 

Read more at prnewswire.com

ADITXT INC

NASDAQ:ADTX (7/25/2025, 8:00:00 PM)

After market: 1.2099 +0.02 (+1.67%)

1.19

-0.07 (-5.56%)



Find more stocks in the Stock Screener

Follow ChartMill for more